A.J. BIOTECH

At AJ Pharma Holding, we strongly believe that investing in healthcare and technology is the best way to drive our aspiration of providing access to affordable and quality healthcare for all. The vision, was firmly established in 2012, when AJ Pharma Holding was established by the Aljomaih Group as a dedicated healthcare investment company in Malaysia.

As part of one of the world’s leading conglomerates in the consumer and commercial sectors, we believe in a holistic approach to healthcare and wellbeing. Our businesses demonstrate their innovative capabilities by translating customer and end-user insights into meaningful solutions that improve the quality of people’s lives. Through a progressive partnership and collaboration model, our core businesses AJ Biologics and AJ Research & Pharma are geared towards shaping a secure future for Malaysia’s public health sector while helping people live a healthier life.

This vision is further enhanced through the transmission of technology, innovation and knowledge by AJ Vaccines, a vaccine producer and manufacturer based in Copenhagen Denmark. As a part of the Aljomaih global network, AJ Vaccines acts as a strategic partner to AJ Biologics in Malaysia.

We are establishing Malaysia’s first state-of-the-art vaccine formulation, vaccine production. This will create a balanced vaccine portfolio to meet the country’s public health needs.

AJ Research & Pharma is the commercial arm of AJ Pharma Holding, catering to the branded and generic pharmaceutical, aesthetics, dermo-cosmetics and nutraceutical segments. Headquartered in Malaysia, the company also enjoys a strong presence in ASEAN (namely Vietnam, Singapore, Philippines, Myanmar, Cambodia and Laos), GCC, Middle East and North African markets.

AJ Vaccines produces and markets vaccines from its manufacturing site in central Copenhagen. AJ Vaccines is the result of the acquisition of the vaccine manufacturing arm of the Statens Serum Institute (SSI) by the healthcare investment arm of the Aljomaih Group. Established in 1902, the manufacturing facility was originally owned by the Danish Government and primarily produced sera against diphtheria.